Manufacturer record

Upkar Pharmaceuticals: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

2 batches manufactured by Upkar Pharmaceuticals (Himachal Pradesh) were declared Not of Standard Quality between September 2022 and October 2023. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

2 records linked to Upkar Pharmaceuticals in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
2Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Sep 2022 to Oct 2023

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

2
NSQ batches since 2022
2
Products affected
Assay
Most common failure
Oct 2023
Latest alert

Flagged batches per year

2022 · 12023 · 1

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Aceclofenac, Paracetamol and Serratiopeptidase Tablets (Pain Free-SP Tablets) UTA-22350Mfg 2022-08 · Exp 2024-07 Assay of SerratiopeptidaseAssay RDTL ChandigarhState lab Oct 2023
Sin-DSR (Rabeprazole Sodium (EC) & Domperidone Sustained Release Capsules) UCA-21063Mfg 2021-08 · Exp 2023-07 Assay for Rabeprazole SodiumAssay RDTL GuwahatiState lab Sep 2022

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.